Patient Affordability Growth Drives Revenue and Margin Expansion
Raises Full Year 2026 Gross Margin, Net Income, GAAP EPS and Adjusted EBITDA Guidance
Balance Sheet Supports Continued Investment and Growth
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries,
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries,
Revenues of $28.25 million in Q2’26, up 48.1% from Q2’25
Pharma revenue increased to $14.65 million, an increase of 88.9% versus Q2’25; added 51 net patient affordability programs during the past 12 months,
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries,
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries,
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries,
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries,
Mix Shift Drives Gross and Operating Margin Expansion
Strong Balance Sheet Enables Continued Investment for Profitable Growth
Paysign, Inc. (NASDAQ:PAYS), a leading provider of patient affordability offerings, donor
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries,
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries,
Dynamic Business Rules Demonstrates the Company's Advanced Capabilities in Mitigating Copay Maximizers, Exiting 2025 With 131 Active Programs
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries,
Delivered strong performance with record revenue and improved profitability
Third quarter 2025 total revenues of $21.60 million, up 41.6% from third quarter 2024
Third quarter 2025 net income of $2.22 million, up
